GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Baloxavir marboxil tablets (adults at least 40 kg)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Xofluza

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Baloxavir marboxil tablets (adults at least 40 kg) - selected U.S. labeling

Product / population
Adults weighing at least 40 kg with acute uncomplicated influenza; oral baloxavir tablets. Pediatric and liquid formulations are outside this summary.
Renal measure
CrCl mL/min describes study evidence, not a severe-renal dose rule.
Labeled basic dosing

Give a single oral dose within 48 hours of symptom onset: 40 mg for weight 40 to less than 80 kg, or 80 mg for weight at least 80 kg.

Renal information and dialysis

No clinically meaningful pharmacokinetic difference was seen at CrCl 50 mL/min or greater. Severe-renal pharmacokinetics have not been evaluated; this label does not establish a numeric severe-renal or dialysis adjustment.

Selected warnings and limits

Avoid coadministration with dairy/calcium-fortified drinks and polyvalent-cation antacids, laxatives or supplements because absorption may fall.

Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e49e1a61-1b7c-4be5-ac84-af6240b511e7

Scope: Selected dosing/renal sections read; concise local summary, not full prescribing information. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Baloxavir marboxil tablets (adults at least 40 kg) - selected U.S. labeling

Adults weighing at least 40 kg with acute uncomplicated influenza; oral baloxavir tablets. Pediatric and liquid formulations are outside this summary.

Renal method: CrCl mL/min describes study evidence, not a severe-renal dose rule.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF baloxavir - renal and hemodialysis recommendations

Adults weighing at least 40 kg with acute uncomplicated influenza; oral baloxavir tablets. Pediatric and liquid formulations are outside this summary.

Renal method: Weight-based dosing; qualitative renal/HD guidance
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Official source

Baloxavir marboxil tablets (adults at least 40 kg) - selected U.S. labeling

Adults weighing at least 40 kg with acute uncomplicated influenza; oral baloxavir tablets. Pediatric and liquid formulations are outside this summary.

Method: CrCl mL/min describes study evidence, not a severe-renal dose rule.

Renal information and dialysisRead this complete source summary
Professional source

UCSF baloxavir - renal and hemodialysis recommendations

Adults weighing at least 40 kg with acute uncomplicated influenza; oral baloxavir tablets. Pediatric and liquid formulations are outside this summary.

Method: Weight-based dosing; qualitative renal/HD guidance

Source-specific renal protocolRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeBaloxavir marboxil tablets (adults at least 40 kg) - selected U.S. labelingUCSF baloxavir - renal and hemodialysis recommendations
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e49e1a61-1b7c-4be5-ac84-af6240b511e7

Product and population scope

Adults weighing at least 40 kg with acute uncomplicated influenza; oral baloxavir tablets. Pediatric and liquid formulations are outside this summary.

RDM31-baloxavir-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Baloxavir marboxil tablets (adults at least 40 kg) - selected U.S. labeling

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adults weighing at least 40 kg with acute uncomplicated influenza; oral baloxavir tablets. Pediatric and liquid formulations are outside this summary.

Renal method: CrCl mL/min describes study evidence, not a severe-renal dose rule.
Source date: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05

Selected dosing/renal sections read; concise local summary, not full prescribing information.

Labeled basic dosing

Give a single oral dose within 48 hours of symptom onset: 40 mg for weight 40 to less than 80 kg, or 80 mg for weight at least 80 kg.

RDM31-baloxavir-label-dose · Source locator: 2.1, 2.2 Table 1

Renal information and dialysis

No clinically meaningful pharmacokinetic difference was seen at CrCl 50 mL/min or greater. Severe-renal pharmacokinetics have not been evaluated; this label does not establish a numeric severe-renal or dialysis adjustment.

RDM31-baloxavir-label-renal · Source locator: 12.3: Specific Populations

Selected warnings and limits

Avoid coadministration with dairy/calcium-fortified drinks and polyvalent-cation antacids, laxatives or supplements because absorption may fall.

RDM31-baloxavir-label-limits · Source locator: 2.1; 7.1

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e49e1a61-1b7c-4be5-ac84-af6240b511e7
Retrieved
2026-09-05
DailyMed Set ID
e49e1a61-1b7c-4be5-ac84-af6240b511e7
Renal-function method
CrCl mL/min describes study evidence, not a severe-renal dose rule.
Source date/version
Label revision date not separately recorded; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or label PDF.
Local summary SHA-256
39ec25ab4fa027372ac4ac0fa3d376b0b16352ac457e778722780917d044ac71
Separate professional-source layer

University and professional protocols

Professional

UCSF baloxavir - renal and hemodialysis recommendations

Open original reference

Open / share this exact local source

University of California San Francisco (UCSF) · Adults weighing at least 40 kg with acute uncomplicated influenza; oral baloxavir tablets. Pediatric and liquid formulations are outside this summary.

Renal method: Weight-based dosing; qualitative renal/HD guidance
Source date: Revision date not stated on the reviewed page.
Retrieved: 2026-09-05

Separate professional-source protocol; not automatically equivalent to product labeling.

Source-specific renal protocol

UCSF recommends 40 mg orally once for uncomplicated influenza at 40-79 kg and 80 mg once for its printed >80 kg group. It states that neither renal impairment nor hemodialysis requires dose adjustment.

RDM31-baloxavir-prof-1 · Source locator: Adult and intermittent/continuous hemodialysis tables

Source-specific limits

The printed weight groups omit exact 80 kg and fractional weights above 79 but below 80. The U.S. label defines 40 to <80 and >=80 for this adult scope. The institutional renal recommendation goes beyond the label's severe-renal pharmacokinetic evidence.

Source identity and provenance
Source
https://idmp.ucsf.edu/content/baloxavir-marboxil
Retrieved
2026-09-05
Renal-function method
Weight-based dosing; qualitative renal/HD guidance
Source date/version
Revision date not stated on the reviewed page.
Hash meaning
SHA-256 identifies the local paraphrase, not original source bytes.
Local summary SHA-256
1d3d3defea945f5b8f1231d5bb544cbb6fca7319209693ce612001672076471f

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e49e1a61-1b7c-4be5-ac84-af6240b511e7
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
f0c3a62c864837e9140d80a44f5d1aea6ace969092693258db031356aebe6187
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report